• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CardioVascular BioTherapeutics to Present at 2006 UBS Life Sciences Conference

Posted on: Tuesday, 12 September 2006, 09:00 CDT

CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced that Daniel C. Montano, President and CEO is presenting the progress of the company's drug candidates to treat cardiovascular disease at the 2006 UBS Global Life Sciences Conference. The event will be held from September 25 to 28 at the Grand Hyatt Hotel in New York City. Mr. Montano is scheduled to speak on September 25 at 8:30 a.m.

The live audio webcast of Mr. Montano's presentation and the subsequent archived recording will be available on the "Investors" section of the company's website, at www.cvbt.com, and on the UBS Investment Bank website at www.ibb.ubs.com.

"CardioVascular BioTherapeutics is dedicated to the development of therapies for the treatment of cardiovascular disease, which afflicts more than 71 million people in the US. We are making great strides in our FDA-authorized human clinical trials for our drug candidates with Cardio Vascu-Grow(TM) as the active ingredient, which is currently being investigated for its ability to stimulate the growth of new blood vessels to create perfusion of blood supply to impaired organs and tissues that could benefit from additional blood supply. I look forward to providing an update on our current FDA-authorized clinical trials and progress in our studies to treat a variety of cardio vascular diseases," said Mr. Montano.

CVBT's Cardio Vascu-Grow(TM) contains a protein that is a member of the fibroblast growth factor family that has been shown to stimulate the growth and multiplication of blood vessels, a process called angiogenesis. When blood perfusion is established in affected areas, patients with cardiovascular diseases may experience an increase in life expectancy and quality of life.

The UBS Life Sciences Conference is reported to be among the largest health care investor conferences in the world. It features presentations by more than 360 public and private companies representing biotechnology, medical device manufacturers, pharmaceuticals and specialty pharmaceutical. Senior executives from the leading pharmaceutical, biotechnology and medical technology companies will further provide their insight and outlook on the global life sciences industry. To access audio transmissions and the conference agenda please go to the UBS Investment Bank website at www.ibb.ubs.com.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. The company is currently conducting two FDA-authorized clinical trials: one in coronary artery disease in no-option heart patients, and one in impaired wound healing seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral artery disease of the legs and stroke recovery. A foreign proof-of-concept clinical trial relating to chronic back pain believed to be caused by impaired or blocked lumbar arteries has also been initiated.

Cardio Vascu-Grow is a trademark of CardioVascular BioTherapeutics, Inc.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, results of future clinical and pre-clinical trials, differences in patient outcomes, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category